Floatz logo

889 assets in Neoplasm

Therapeutic assets addressing Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Tyra-200
Neoplasm
Tyra Biosciences, IncP1C (36)
Uclm802 Cell
Neoplasm
Peking UniversityP1C (36)
vg2025
Neoplasm
Virogin Biotech Canada LtdP1C (36)
vrt106
Neoplasm
Guangzhou Virotech Pharmaceutical Co., Ltd.P1C (36)
wbc100 bid
Neoplasm
Zhejiang UniversityP1C (36)
wbc100 qd
Neoplasm
Zhejiang UniversityP1C (36)
xb628
Neoplasm
ExelixisP1C (36)
yl-13027
Neoplasm
Shanghai YingLi Pharmaceutical Co. Ltd.P1C (36)
Zanzalintinib
Neoplasm
ExelixisP1C (36)
ABO2109
Neoplasm
Suzhou Abogen Biosciences Co., Ltd.Early P1C (34)
il-15 enhanced engineered nk cells
Neoplasm
Genovn Therapeutics (Suzhou) Co., Ltd.Early P1C (34)
rt01-89zr
Neoplasm
Nanolattix Biotechnology Co., Ltd.Early P1C (34)
Sasanlimab
Neoplasm
PfizerP2C (34)
[18F]SF-DEVD-2
Neoplasm
Affiliated Hospital of Jiangnan UniversityEarly P1C (33)
89zr-dfo-n-suc-c9scfv
Neoplasm
Var2 PharmaceuticalsEarly P1C (33)
89Zr-DFO-N-Suc-F8scFv
Neoplasm
Var2 PharmaceuticalsEarly P1C (33)
Anti Alpp Car-T Cells Treatment
Neoplasm
TCRCure Biopharma Ltd.Early P1C (33)
azd9592
Neoplasm
Presage BiosciencesEarly P1C (33)
ben101
Neoplasm
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineEarly P1C (33)
Enhanced Alpp Car-T Treatment
Neoplasm
TCRCure Biopharma Ltd.Early P1C (33)
Fast Car T Cells
Neoplasm
Shanghai Cell Therapy Group Co.,LtdEarly P1C (33)
gt316
Neoplasm
Grit BiotechnologyEarly P1C (33)
ibi3026
Neoplasm
Innovent Biologics Technology Limited (Shanghai R&D Center)Early P1C (33)
Immunoglobulin G1-Kappa/Lambda, Anti-[Homo Sapiens Pdcd1 (Programmed Cell Death 1, Pd1, Pd-1, Cd279) And Havcr2 (Hepatitis A Virus Cellular Receptor 2, T Cell Immunoglobulin And Mucin Domains Family Member 3, Tim3, Tim-3, Timd3, Cd366)], Humanized And Homo Sapiens Monoclonal Antibody, Bispecific, Bivalent
Neoplasm
Presage BiosciencesEarly P1C (33)
ksh01
Neoplasm
TCRx Therapeutics Co.LtdEarly P1C (33)
lm103
Neoplasm
Suzhou BlueHorse Therapeutics Co., Ltd.Early P1C (33)
lm303
Neoplasm
Suzhou BlueHorse Therapeutics Co., Ltd.Early P1C (33)
rd133
Neoplasm
The First Affiliated Hospital with Nanjing Medical UniversityEarly P1C (33)
rd14-01 cell
Neoplasm
Shen LinEarly P1C (33)
Rilvegostomig
Neoplasm
Presage BiosciencesEarly P1C (33)
Rock2 Inhibitor Kd025
Neoplasm
jianming xuEarly P1C (33)
Volrustomig
Neoplasm
Presage BiosciencesEarly P1C (33)
αpd1/ctla4-msln-car t cells
Neoplasm
Shanghai Cell Therapy Group Co.,LtdEarly P1C (33)
Interleukin-11
Neoplasm
Jun wangN/AD (30)
M-Sympathol
Neoplasm
Zhejiang Cancer HospitalN/AD (30)
Noradrenaline
Neoplasm
Zhejiang Cancer HospitalN/AD (30)
Zandelisib
Neoplasm
Salubris Biotherapeutics IncP1/2D (30)
Sumoylation Inhibitor Tak-981
Neoplasm
TakedaP1/2D (29)
[68ga]ga-oncoacp3
Neoplasm
Peking University First HospitalN/AD (28)
68Ga-HTK03149
Neoplasm
British Columbia Cancer AgencyN/AD (28)
18F-WL12
Neoplasm
Peking University Cancer Hospital & InstituteN/AD (26)
[68Ga]Ga-THP-PDL1-3
Neoplasm
Hua ZhuN/AD (26)
68Ga-WL12
Neoplasm
Peking University Cancer Hospital & InstituteN/AD (26)
Folactis
Neoplasm
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolN/AD (26)
her2-e-cart cells
Neoplasm
su haichuanN/AD (26)
Personalized Neoantigen Tumor Vaccine
Neoplasm
YueJuan ChengN/AD (26)
qh104 cell
Neoplasm
Cancer Institute and Hospital, Chinese Academy of Medical SciencesN/AD (26)
Showing 801 to 850 of 889 assets
PreviousPage 17 of 18Next